Egle Stukaite-Ruibiene Rimvydas Norvilas Vaidas Dirse Sigita Stankeviciene Goda Elizabeta Vaitkeviciene
10.3389/pore.2022.1610570
Pathol Oncol Res
2022 Sep 12;28:1610570.
bcr-abl1-like acute lymphoblastic leukemia case report imatinib targeted therapy tyrosine kinase inhibitors
CC BY
https://pubmed.ncbi.nlm.nih.gov/36172171/
Antineoplastic Agents / therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Antineoplastic Agents / therapeutic use Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics Case Reports Adolescent Benzamides Gene Fusion Humans Imatinib Mesylate / therapeutic use Nuclear Pore Complex Proteins / genetics Oncogene Proteins, Fusion / genetics Oncogene Proteins, Fusion / metabolism Piperazines / pharmacology Protein Kinase Inhibitors / pharmacology Protein Kinase Inhibitors / therapeutic use Protein Kinases / genetics Protein Kinases / metabolism Pyrimidines / therapeutic use Antineoplastic Agents Benzamides NUP214 protein, human Nuclear Pore Complex Proteins Oncogene Proteins, Fusion Piperazines Protein Kinase Inhibitors Pyrimidines Imatinib Mesylate Protein Kinases
PMC9510372
36172171
Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214:: ABL1 Gene Fusion
2022